Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

odanacatib

- PMLiVE

Merck misses revenue targets as Singulair slumps

Asthma drug hit hard by generic competition in the US

Novartis building

France, Germany and Spain join list of countries banning Novartis vaccines

Flu vaccines Agrippal and Fluad withdrawn after some batches found to be contaminated

- PMLiVE

UCB’s chair Gerhard Mayr joins Almirall board

He becomes an independent director of the Spanish pharma company

Novartis building

NICE backs Novartis’ Tobi Podhaler in cystic fibrosis

But draft guidance doesn't recommend Forest’s Colobreathe

- PMLiVE

Amgen buoyant as profits rise in Q3

Increases 2012 revenue and earnings forecasts

Europe set to approve first Glivec generic

CHMP backs Teva version of Novartis' blockbuster cancer drug

- PMLiVE

Amgen’s Anna Richo joins UCB as executive VP and general counsel

Meanwhile, Cynthia Patton takes over as Amgen’s senior VP and chief compliance officer

Pilot study combines patient-reported outcomes and medical records

Quintiles concludes patients can be recruited directly for observational studies

- PMLiVE

Merck & Co pays €110m upfront for AiCuris’ CMV portfolio

Lead candidate is orphan drug letermovir for transplant patients

- PMLiVE

Merck says osteoporosis drug clears phase II trial

Odanacatib on track for 2013 filing

Novartis building

Gilenya cuts early relapse, brain loss in MS patients

Boosts prospects for oral drug as competitors emerge

- PMLiVE

GSK expands open-source research project in TB

Opens up compound library and extends data transparency project

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links